Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,744.20 -202.73 (-0.52%) Hang Seng
19,254.80 +34.18 (+0.18%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,858.77 -1,203.34 (-1.69%) CMC Crypto 200
1,475.36 -13.18 (-0.89%)
SNY Sep 2024 57.500 call
| Previous close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.0000 |
| Ask | 1.5500 |
| Strike | 57.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.4500 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 22 |
ZacksSanofi (SNY) Signs Deal for AI-Powered Drug Development
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
BenzingaChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects. Also Read: Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings. Sanofi said the partnership with OpenAI will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources. The three teams will combine data, software, and tuned models t
GlobeNewswirePress Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind w
